ALB and metabolic syndrome: Therefore, we evaluated whether controlling MetS in hypertensive patients through the ARB fimasartan reduced the albumin/creatinine ratio (ACR; a proxy for organ damage) and microalbuminuria, a strong predictor of future cardiovascular events.